Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bluefin anti-IL1RAP PBD ADC series (US11248054B2)
- Development stage
- Unknown
- Lead developer
- Bluefin Biomedicine
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Bluefin anti-IL1RAP PBD ADC series (US11248054B2): sourced facts only. name: "Anti-IL1RAP antibodies and antibody drug conjugates" [1] target: "Anti-IL1RAP antibodies and antibody drug conjugates" [1] developer: "Bluefin Biomedicine Inc" [1] modality: "the DNA damaging agent is a PBD." [1]
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)
Beyond the preview
Go deeper on Bluefin anti-IL1RAP PBD ADC series (US11248054B2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bluefin anti-IL1RAP PBD ADC series (US11248054B2).